Insider Selling: ICU Medical, Inc. (NASDAQ:ICUI) Director Sells 600 Shares of Stock

ICU Medical, Inc. (NASDAQ:ICUI) Director Elisha W. Finney sold 600 shares of ICU Medical stock in a transaction on Monday, May 19th. The shares were sold at an average price of $138.92, for a total value of $83,352.00. Following the completion of the transaction, the director now owns 3,252 shares in the company, valued at $451,767.84. The trade was a 15.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

ICU Medical Stock Down 1.0%

ICU Medical stock traded down $1.32 during midday trading on Tuesday, hitting $136.69. 56,259 shares of the stock were exchanged, compared to its average volume of 276,150. ICU Medical, Inc. has a 1 year low of $100.91 and a 1 year high of $196.26. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. The firm has a market cap of $3.36 billion, a P/E ratio of -29.80 and a beta of 0.87. The company has a 50 day moving average price of $140.78 and a two-hundred day moving average price of $153.61.

ICU Medical (NASDAQ:ICUI) last announced its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.49. ICU Medical had a positive return on equity of 5.05% and a negative net margin of 4.74%. The business had revenue of $599.49 million for the quarter, compared to analyst estimates of $574.15 million. During the same period in the previous year, the company earned $0.96 earnings per share. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. On average, sell-side analysts predict that ICU Medical, Inc. will post 4.11 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ICU Medical

Several hedge funds and other institutional investors have recently bought and sold shares of ICUI. Barclays PLC boosted its stake in shares of ICU Medical by 15.6% during the 3rd quarter. Barclays PLC now owns 59,207 shares of the medical instruments supplier’s stock valued at $10,790,000 after buying an additional 8,010 shares during the last quarter. Vanguard Group Inc. grew its holdings in ICU Medical by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 2,682,065 shares of the medical instruments supplier’s stock worth $416,176,000 after acquiring an additional 17,805 shares in the last quarter. Jennison Associates LLC bought a new stake in shares of ICU Medical in the 4th quarter worth about $556,000. Norges Bank acquired a new stake in shares of ICU Medical in the 4th quarter valued at about $40,151,000. Finally, Proficio Capital Partners LLC acquired a new stake in shares of ICU Medical in the 4th quarter valued at about $5,779,000. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently commented on ICUI shares. StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a report on Sunday. KeyCorp cut their price objective on ICU Medical from $209.00 to $191.00 and set an “overweight” rating on the stock in a research report on Monday, April 21st. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research report on Tuesday, April 8th. Finally, Raymond James lowered their target price on ICU Medical from $197.00 to $187.00 and set a “strong-buy” rating for the company in a research note on Friday, May 9th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $192.67.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.